Literature DB >> 11877320

5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro.

R A Borman1, N S Tilford, D W Harmer, N Day, E S Ellis, R L G Sheldrick, J Carey, R A Coleman, G S Baxter.   

Abstract

1. 5-Hydroxytryptamine (5-HT) is known to produce a number of different effects in the gastrointestinal tract of various species, and has been proposed to play a key role in a number of intestinal disorders in man, including irritable bowel syndrome (IBS), although the receptors involved have yet to be established. The aim of the present study was to investigate the distribution and function of 5-HT(2B) receptors in human colon, and to establish their possible role in the aetiology of IBS. 2. The distribution of 5-HT(2B) receptor mRNA and protein were investigated by quantitative RT - PCR, Western analysis and immunocytochemistry. High levels of both mRNA and protein for 5-HT(2B) receptors were found throughout the human gastrointestinal tract, and in particular in colon, where 5-HT(2B) receptors were found predominantly in the longitudinal and circular smooth muscle layers within the muscularis externa, and in the myenteric nerve plexus lying between these two layers. 3. Electrical field stimulation of longitudinal muscle preparations of human colon mounted in organ baths resulted in neuronally-mediated contractile responses, that were significantly potentiated by application of 5-HT (up to 10(-7) M), with a pEC(50) of 8.2 +/- 0.1 (n=49 donors). The response to 5-HT was inhibited by a number of selective 5-HT(2B) receptor antagonists. 4. This study has shown for the first time that, in contrast to animal studies, the excitatory effects of 5-HT in human colon are mediated by 5-HT(2B) receptors. It is proposed that these receptors contribute to the putative 5-HT-induced colonic smooth muscle hypersensitivity associated with IBS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877320      PMCID: PMC1573235          DOI: 10.1038/sj.bjp.0704571

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle.

Authors:  N H Prins; M R Briejer; P J Van Bergen; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

2.  Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestine.

Authors:  R A Borman; D E Burleigh
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

3.  How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated?

Authors:  D MacKay
Journal:  J Pharm Pharmacol       Date:  1978-05       Impact factor: 3.765

4.  Human colonic mucosa possesses a mixed population of 5-HT receptors.

Authors:  R A Borman; D E Burleigh
Journal:  Eur J Pharmacol       Date:  1996-08-15       Impact factor: 4.432

5.  5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons.

Authors:  J R Grider; J F Kuemmerle; J G Jin
Journal:  Am J Physiol       Date:  1996-05

6.  Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT.

Authors:  R A Borman; D E Burleigh
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  Modulation of submucosal cholinergic neurons by 5-hydroxytryptamine and neuropeptides.

Authors:  W M Yau; J A Dorsett; M L Youther
Journal:  Am J Physiol       Date:  1990-12

8.  5-hydroxytryptamine release into human jejunum by cholera toxin.

Authors:  C P Bearcroft; D Perrett; M J Farthing
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

Review 9.  The importance of 5-hydroxytryptamine receptors in the gut.

Authors:  N W Read; K A Gwee
Journal:  Pharmacol Ther       Date:  1994 Apr-May       Impact factor: 12.310

10.  Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle.

Authors:  F S Tam; K Hillier; K T Bunce
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

View more
  25 in total

Review 1.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

2.  Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology.

Authors:  A K Bassil; C M Taylor; V J N Bolton; K M Gray; J D Brown; L Cutler; S G Summerfield; G Bruton; W J Winchester; K Lee; G J Sanger
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

3.  The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.

Authors:  J A M Smith; D T Beattie; D Marquess; J P Shaw; R G Vickery; P P A Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-16       Impact factor: 3.000

4.  Divergent changes to muscarinic and serotonergic signalling following colitis.

Authors:  R W Wells; M G Blennerhassett
Journal:  Gut       Date:  2005-07-13       Impact factor: 23.059

5.  Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.

Authors:  Cindy Weidmann; Julie Bérubé; Léo Piquet; Arnaud de la Fouchardière; Solange Landreville
Journal:  Clin Exp Metastasis       Date:  2018-04-25       Impact factor: 5.150

6.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

Review 7.  Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.

Authors:  Terry-Elinor Reid; Krishna Kumar; Xiang Simon Wang
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 8.  Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.

Authors:  C Stasi; M Bellini; G Bassotti; C Blandizzi; S Milani
Journal:  Tech Coloproctol       Date:  2014-01-15       Impact factor: 3.781

9.  Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.

Authors:  Nicholas L Meyers; Roger I Hickling
Journal:  Drugs R D       Date:  2008

10.  The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.

Authors:  D T Beattie; J A M Smith; D Marquess; R G Vickery; S R Armstrong; T Pulido-Rios; J L McCullough; C Sandlund; C Richardson; N Mai; P P A Humphrey
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.